Skip to main content
Premium Trial:

Request an Annual Quote

Genmab, ACE BioSciences to Develop Antibody-based Fungicide

NEW YORK, Nov. 17 (GenomeWeb News) - Genmab and ACE BioSciences said today that they have agreed to develop an antibody-based fungicide against a protein target on Aspergillus fumigatus.

 

The arrangement is part of a broader drug development partnership between the companies under which ACE discovers novel protein targets in four disease areas and Genmab contributes its human antibody technology. The companies share costs and commercialization rights equally under the alliance, they said.

 

"ACE BioSciences's target discovery skills and Genmab's antibody development capabilities are an ideal combination for discovery and development of antibody based treatments for infectious diseases," Genmab CEO Lisa Drakeman said in a statement. "Fungal infections are becoming an increasingly urgent health threat and, despite not being adequately treated, currently represent a multi-billion dollar market."

 

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.